You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 12, 2024

DEXYCU KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Dexycu Kit, and when can generic versions of Dexycu Kit launch?

Dexycu Kit is a drug marketed by Eyepoint Pharms and is included in one NDA. There are five patents protecting this drug.

This drug has forty-five patent family members in twenty-one countries.

The generic ingredient in DEXYCU KIT is dexamethasone. There are thirty-nine drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Dexycu Kit

A generic version of DEXYCU KIT was approved as dexamethasone by HIKMA on September 15th, 1983.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DEXYCU KIT?
  • What are the global sales for DEXYCU KIT?
  • What is Average Wholesale Price for DEXYCU KIT?
Summary for DEXYCU KIT
Drug patent expirations by year for DEXYCU KIT
Recent Clinical Trials for DEXYCU KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
EyePoint Pharmaceuticals, Inc.Phase 3
University of MiamiPhase 2
Karyopharm Therapeutics IncPhase 2

See all DEXYCU KIT clinical trials

Pharmacology for DEXYCU KIT

US Patents and Regulatory Information for DEXYCU KIT

DEXYCU KIT is protected by five US patents.

Patents protecting DEXYCU KIT

Dose guides for injection syringe
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF POSTOPERATIVE INFLAMMATION

Use of sustained release dexamethasone in post-cataract surgery inflammation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF POSTOPERATIVE INFLAMMATION

Use of sustained release dexamethasone in post-cataract surgery inflammation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose guides for injection syringe
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Systems, kits and methods for loading and delivering a small volume dose from a syringe
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF LOADING MEDICATION INTO A SYRINGE AND DELIVERING THE MEDICATION TO A TREATMENT SITE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eyepoint Pharms DEXYCU KIT dexamethasone SUSPENSION;INTRAOCULAR 208912-001 Feb 9, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Eyepoint Pharms DEXYCU KIT dexamethasone SUSPENSION;INTRAOCULAR 208912-001 Feb 9, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Eyepoint Pharms DEXYCU KIT dexamethasone SUSPENSION;INTRAOCULAR 208912-001 Feb 9, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Eyepoint Pharms DEXYCU KIT dexamethasone SUSPENSION;INTRAOCULAR 208912-001 Feb 9, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Eyepoint Pharms DEXYCU KIT dexamethasone SUSPENSION;INTRAOCULAR 208912-001 Feb 9, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for DEXYCU KIT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
AbbVie Deutschland GmbH & Co. KG Ozurdex dexamethasone EMEA/H/C/001140
Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
Authorised no no no 2010-07-26
THERAVIA Neofordex dexamethasone EMEA/H/C/004071
Treatment of multiple myeloma.
Authorised no no no 2016-03-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for DEXYCU KIT

See the table below for patents covering DEXYCU KIT around the world.

Country Patent Number Title Estimated Expiration
South Korea 101978235 ⤷  Sign Up
Brazil 112013027428 guias de dose para seringa de injeção ⤷  Sign Up
Spain 2726805 ⤷  Sign Up
South Korea 102081808 ⤷  Sign Up
Slovenia 2701773 ⤷  Sign Up
South Korea 102245354 ⤷  Sign Up
South Korea 20190042765 주사기용 투여량 가이드 (DOSE GUIDES FOR INJECTION SYRINGE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DEXYCU KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1581193 SPC/GB12/047 United Kingdom ⤷  Sign Up PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727
1429780 SPC/GB12/058 United Kingdom ⤷  Sign Up PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1429780 13C0012 France ⤷  Sign Up PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.